BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $103,197.25 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 2,825 shares of the company’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $36.53, for a total transaction of $103,197.25. Following the completion of the sale, the chief marketing officer now directly owns 80,029 shares of the company’s stock, valued at $2,923,459.37. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Todd Berard also recently made the following trade(s):

  • On Friday, March 26th, Todd Berard sold 2,120 shares of BioLife Solutions stock. The shares were sold at an average price of $35.01, for a total transaction of $74,221.20.
  • On Tuesday, March 16th, Todd Berard sold 6,160 shares of BioLife Solutions stock. The shares were sold at an average price of $36.72, for a total transaction of $226,195.20.
  • On Thursday, February 18th, Todd Berard sold 1,882 shares of BioLife Solutions stock. The shares were sold at an average price of $40.67, for a total transaction of $76,540.94.
  • On Tuesday, February 16th, Todd Berard sold 12,324 shares of BioLife Solutions stock. The shares were sold at an average price of $44.48, for a total transaction of $548,171.52.

Shares of BLFS opened at $34.86 on Thursday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -47.75, a P/E/G ratio of 50.41 and a beta of 1.55. BioLife Solutions, Inc. has a fifty-two week low of $8.88 and a fifty-two week high of $47.97. The business’s 50-day moving average is $37.99 and its 200-day moving average is $36.34.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Sunday, March 21st. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.04). The business had revenue of $14.73 million during the quarter, compared to analyst estimates of $13.43 million. BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. On average, equities analysts predict that BioLife Solutions, Inc. will post 0.01 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. increased its holdings in shares of BioLife Solutions by 5.7% in the 4th quarter. Victory Capital Management Inc. now owns 75,447 shares of the medical equipment provider’s stock valued at $3,010,000 after purchasing an additional 4,039 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of BioLife Solutions by 63.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 119,245 shares of the medical equipment provider’s stock valued at $3,418,000 after purchasing an additional 46,474 shares during the period. BlackRock Inc. increased its holdings in BioLife Solutions by 82.9% in the third quarter. BlackRock Inc. now owns 1,111,337 shares of the medical equipment provider’s stock worth $32,162,000 after buying an additional 503,659 shares during the last quarter. Brookfield Asset Management Inc. acquired a new position in BioLife Solutions in the fourth quarter worth approximately $586,000. Finally, Jennison Associates LLC acquired a new position in BioLife Solutions in the fourth quarter worth approximately $17,934,000. Institutional investors own 67.66% of the company’s stock.

A number of analysts have commented on the stock. Maxim Group upped their price objective on shares of BioLife Solutions from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, March 23rd. Benchmark raised shares of BioLife Solutions from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Monday, March 29th. Zacks Investment Research raised shares of BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday, January 6th. KeyCorp upped their price objective on shares of BioLife Solutions from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 29th. Finally, Stephens upped their price objective on shares of BioLife Solutions from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, March 23rd. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $45.10.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also: How do investors use RSI to grade stocks?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.